U.S., June 14 -- ClinicalTrials.gov registry received information related to the study (NCT07019844) titled 'PSMA PET for the Staging and Management of Hepatocellular Carcinoma' on June 05.
Brief Summary: This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET/CT improves diagnostic accuracy for indeterminate liver lesions (LI-RADS 3 and 4), enhances staging precision in treatment-naive patients, and provides more accurate assessment of treatment response in patients undergoing locoregional therapy (LRT). The goal is to assess...